Table of Contents
International Journal of Molecular Imaging
Volume 2011 (2011), Article ID 175352, 9 pages
http://dx.doi.org/10.1155/2011/175352
Research Article

Functional Imaging of Pheochromocytoma with 68Ga-DOTATOC and 68C-HED in a Genetically Defined Rat Model of Multiple Endocrine Neoplasia

1Department of Nuclear Medicine, Johannes Gutenberg University of Mainz, Langenbeck Strasse 1, 55131 Mainz, Germany
2Institute of Pathology, Helmholtz Zentrum München, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany
3Institute of Pathology, University of Bern, Murtenstrasse 31, 3010 Bern, Switzerland
4Department of Medicine, Klinikum Großhadern, Ludwig Maximilians University (LMU), Marchioninistrasse 15, 81377 Munich, Germany
5Department of Nuclear Medicine, Technical University Munich, Ismaninger Strasse 22, 81675 Munich, Germany

Received 12 January 2011; Accepted 7 March 2011

Academic Editor: Björn Wängler

Copyright © 2011 Matthias Miederer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. John, W. H. Ziegler, D. Hauri, and P. Jaeger, “Pheochromocytomas: can malignant potential be predicted?” Urology, vol. 53, no. 4, pp. 679–683, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. A. S. Tischler, “Pheochromocytoma and extra-adrenal paraganglioma: updates,” Archives of Pathology and Laboratory Medicine, vol. 132, no. 8, pp. 1272–1284, 2008. View at Google Scholar · View at Scopus
  3. B. L. Shulkin, I. Ilias, J. C. Sisson, and K. Pacak, “Current trends in functional imaging of pheochromocytomas and paragangliomas,” Annals of the New York Academy of Sciences, vol. 1073, pp. 374–382, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. K. C. Loh, P. A. Fitzgerald, K. K. Matthay, P. P. B. Yeo, and D. C. Price, “The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (I-MIBG): a comprehensive review of 116 reported patients,” Journal of Endocrinological Investigation, vol. 20, no. 11, pp. 648–658, 1997. View at Google Scholar · View at Scopus
  5. J. C. Sisson, B. Shapiro, W. H. Beierwaltes et al., “Radiopharmaceutical treatment of malignant pheochromocytoma,” Journal of Nuclear Medicine, vol. 25, no. 2, pp. 197–206, 1984. View at Google Scholar
  6. G. K. Gedik, C. A. Hoefnagel, E. Bais, and R. A. Valdés Olmos, “I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 4, pp. 725–733, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B. Grossman, “The diagnosis and management of malignant phaeochromocytoma and paraganglioma,” Endocrine-Related Cancer, vol. 14, no. 3, pp. 569–585, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Fritz, A. Walch, K. Piotrowska et al., “Recessive transmission of a multiple endocrine neoplasia syndrome in the rat,” Cancer Research, vol. 62, no. 11, pp. 3048–3051, 2002. View at Google Scholar · View at Scopus
  9. N. S. Pellegata, L. Quintanilla-Martinez, H. Siggelkow et al., “Germ-line mutations in p27 cause a multiple endocrine neoplasia syndrome in rats and humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 42, pp. 15558–15563, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Quintanilla-Martinez, M. Kremer, K. Specht et al., “Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: stat 3 activation and cyclin D1 dysregulation are mutually exclusive events,” American Journal of Pathology, vol. 162, no. 5, pp. 1449–1461, 2003. View at Google Scholar · View at Scopus
  11. S. Molatore, E. Kiermaier, C. B. Jung et al., “Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors,” Molecular Cancer, vol. 9, article no. 116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. R. V. Lloyd, L. Jin, X. Qian, and E. Kulig, “Aberrant p27(kip1) expression in endocrine and other tumors,” American Journal of Pathology, vol. 150, no. 2, pp. 401–407, 1997. View at Google Scholar · View at Scopus
  13. L. Quintanilla-Martinez, C. Thieblemont, F. Fend et al., “Mantle cell lymphomas lack expression of p27(kip1), a cyclin-dependent kinase inhibitor,” American Journal of Pathology, vol. 153, no. 1, pp. 175–182, 1998. View at Google Scholar · View at Scopus
  14. H. M. Brown, R. A. Komorowski, S. D. Wilson, M. J. Demeure, and Y. R. Zhu, “Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation. A positive correlation between MIB-1 staining and malignant tumor behavior,” Cancer, vol. 86, no. 8, pp. 1583–1589, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. L. D. R. Thompson, “Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases,” American Journal of Surgical Pathology, vol. 26, no. 5, pp. 551–566, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Casini Raggi, A. Calabrò, D. Renzi et al., “Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa,” Clinical Cancer Research, vol. 8, no. 2, pp. 419–427, 2002. View at Google Scholar · View at Scopus
  17. M. Miederer, S. Seidl, A. Buck et al., “Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in Ga-DOTATOC PET/CT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 1, pp. 48–52, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. E. E. Elder, D. Xu, A. Höög et al., “KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma,” Modern Pathology, vol. 16, no. 3, pp. 246–255, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. C. August, K. August, S. Schroeder et al., “CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas,” Modern Pathology, vol. 17, no. 9, pp. 1119–1128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. B. L. Shulkin, D. M. Wieland, M. Schwaiger et al., “PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma,” Journal of Nuclear Medicine, vol. 33, no. 6, pp. 1125–1131, 1992. View at Google Scholar · View at Scopus
  21. M. U. Khan, S. Khan, S. El-Refaie, Z. Win, D. Rubello, and A. Al-Nahhas, “Clinical indications for Gallium-68 positron emission tomography imaging,” European Journal of Surgical Oncology, vol. 35, no. 6, pp. 561–567, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Forrer, I. Riedweg, H. R. Maecke, and J. Mueller-Brand, “Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 4, pp. 334–340, 2008. View at Google Scholar · View at Scopus
  23. D. Cecchin, F. Lumachi, M. C. Marzola et al., “A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 525–533, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert, “Clinical review: current treatment of malignant pheochromocytoma,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 4, pp. 1217–1225, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. I. M. Chu, L. Hengst, and J. M. Slingerland, “The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy,” Nature Reviews Cancer, vol. 8, no. 4, pp. 253–267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Loda, B. Cukor, S. W. Tam et al., “Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas,” Nature Medicine, vol. 3, no. 2, pp. 231–234, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Nickeleit, S. Zender, F. Sasse et al., “Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition,” Cancer Cell, vol. 14, no. 1, pp. 23–35, 2008. View at Publisher · View at Google Scholar · View at Scopus